Exploring the Role of LRG in Gastrointestinal Cancer Care

Exploring the role of serum Leucine-Rich alfa-2-Glycoprotein as a predictor of gastrointestinal cancer detection, progression and therapeutic effects - Exploring the role of serum Leucine-Rich alfa-2-Glycoprotein as a predictor of gastrointestinal cancer detection, progression and therapeutic effects

Status

Active, not recruiting

Phases

Unknown

Study type

Observational

Source

JPRN

Registry ID

JPRN-UMIN000043631

Enrollment

300

Registered

2021-03-19

Start date

2021-02-03

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Gastrointestinal cancer

Interventions

None listed

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: Patients who will receive an examination and treatment for gastrointestinal cancer or suspected gastrointestinal cancer at Nagoya University Hospital.

Exclusion criteria

Exclusion criteria: Patients under 20 years of age Patients with active infectious disease at the time of enrollment Patients who have been diagnosed with autoimmune diseases and are undergoing treatment. Patients who are deemed inappropriate by the investigator.

Design outcomes

Primary

Measure	Time frame
Correlation of LRG values with disease stage or treatment response	—

Countries

Japan

Contacts

Public ContactSatoshi Furune

Nagoya University Hospital Department of Clinical Oncology and Chemotherapy

s-furune@med.nagoya-u.ac.jp0527441902

Outcome results